Difference between revisions of "Finasteride (Proscar)"
m |
Warner-admin (talk | contribs) m (Text replacement - "http://hemonc.org" to "https://hemonc.org") |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: 5 alpha-reductase inhibitor; inhibits conversion of testosterone to dihydrotestosterone (DHT). Specifically and competitively inhibits Type II 5α-reductase by forming a stable enzyme-drug complex.<ref name="insert">[http://www.merck.com/product/usa/pi_circulars/p/proscar/proscar_pi.pdf Finasteride (Proscar) package insert]</ref><ref>[ | + | Class/mechanism: 5 alpha-reductase inhibitor; inhibits conversion of testosterone to dihydrotestosterone (DHT). Specifically and competitively inhibits Type II 5α-reductase by forming a stable enzyme-drug complex.<ref name="insert">[http://www.merck.com/product/usa/pi_circulars/p/proscar/proscar_pi.pdf Finasteride (Proscar) package insert]</ref><ref>[https://hemonc.org/docs/packageinsert/finasteride.pdf Finasteride (Proscar) package insert (locally hosted backup)]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| Line 8: | Line 8: | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://www.uptodate.com/contents/finasteride-patient-drug-information Finasteride (Proscar) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/finasteride-patient-drug-information Finasteride (Proscar) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/finasteride-patient-drug-information Finasteride (Proscar) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/finasteride-patient-drug-information Finasteride (Proscar) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | ''No antineoplastic label, at this time.'' | ||
| + | *1992-06-19: Initial approval | ||
==Also known as== | ==Also known as== | ||
| Line 18: | Line 22: | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | |||
[[Category:Antiandrogens]] | [[Category:Antiandrogens]] | ||
[[Category:5 alpha-reductase inhibitors]] | [[Category:5 alpha-reductase inhibitors]] | ||
| − | |||
| − | [[Category: | + | [[Category:FDA approved in 1992]] |
Revision as of 19:31, 23 June 2024
General information
Class/mechanism: 5 alpha-reductase inhibitor; inhibits conversion of testosterone to dihydrotestosterone (DHT). Specifically and competitively inhibits Type II 5α-reductase by forming a stable enzyme-drug complex.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
History of changes in FDA indication
No antineoplastic label, at this time.
- 1992-06-19: Initial approval
Also known as
- Brand name: Proscar